TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Aflibercept Injection in Vision Impairment Due to DME

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 years with type 1 or 2 diabetes mellitus~* Subjects with DME secondary to diabetes mellitus involving the center of the macula in the study eye~* Decrease in vision determined to be primarily the result of DME in the study eye~* BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye~Exclusion Criteria:~* Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1~* More than 2 previous macular laser treatments in the study eye~* Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of Day 1~* Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1~* Active proliferative diabetic retinopathy (PDR) in the study eye, with the exception of inactive, regressed PDR~* Uncontrolled diabetes mellitus, as defined by HbA1c \> 12%~* Only 1 functional eye even if that eye is otherwise eligible for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravitreal Aflibercept Injection 2Q4 (Type: EXPERIMENTAL): Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
- Intravitreal Aflibercept Injection 2Q8 (Type: EXPERIMENTAL): Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
- Macular Laser Photocoagulation (Control) (Type: ACTIVE_COMPARATOR): Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Active Video Games in Physically Inactive Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Being 8-13 years old~2. Being preoccupied with technology~3. Being physically inactive~Exclusion Criteria:~1. Having circulatory, respiratory and musculoskeletal disease~2. Having neuropsychiatric diseases~3. History of syncope or seizures~4. History of exercise induced anaphylaxis~5. Morbid obesity~6. Short stature

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Physically inactive children who did not play AVGs.
- Intervention Group (Type: EXPERIMENTAL): Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and ≤ 75 years.~2. Patients with follicular lymphoma grade 1, 2 or 3a, CD20 +, histologically confirmed lymph node biopsy or tissue. Be accepted diagnosis in bone marrow if no accessible lymph nodes and whether it has discarded the mantle LLC, and NHL.~3. Follicular lymphoma patients treated with the combination of rituximab and chemotherapy in first line, which have been refractory or relapsed after having achieved any responses to this first line of pretreatment (excluding radiotherapy).~4. ECOG ≤ 2.~5. Signed written informed consent.~Exclusion Criteria:~1. Clinical suspicion or documentation of histological transformation.~2. Have received prior chemotherapy scheme, first line without Rituximab.~3. Prior autologous or allogeneic.~4. CNS infiltration by LF (primary CNS lymphoma or lymphomatous meningitis).~5. Past or active Hepatitis B (at least one of the following markers HBsAg, HBe Ag, anti-HBc, HBV DNA)~6. HCV infection. HIV infection or other conditions of serious immunosuppression.~7. Previous neoplasms except non-melanoma skin cancer of the cervix or adequately treated.~8. Cardiac function in cardiac patient known or prior treatment with anthracyclines with EF \<50%.~9. Impaired renal function (creatinine\> 1.5 x Upper Limit of Normal, LSN) or a creatinine clearance \<50 ml / h, not related to lymphoma.~10. Impaired liver function (bilirubin, AST / ALT or GGT\> 2 x ULN) were not related to lymphoma.~11. Women who are nursing or pregnant. Women of childbearing potential will be included prior pregnancy test serum / urine negative. Use effective contraception to be kept for 1 year after cessation of rituximab.~12. Patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic and not secondary to lymphoma.~13. Severe acute or chronic infection in activity.~14. Any other concurrent medical or psychological comorbidity that might interfere with participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- R-BMD (Type: EXPERIMENTAL): Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants based on medical history and clinical assessment.~* Between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.~* Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.~* Subjects must have been born full-term, have a weight-to-height Z score of ≥ -2 at the time of enrollment (WHO child growth standard), and be ≥ 3.5 kg at randomization.~* Subject's parents must be available for the duration of trial participation~Exclusion Criteria:~* Use of any investigational medicinal product prior to randomization.~* Previous vaccination against or infection with S. pneumoniae.~* History of anaphylactic shock or an allergic reaction to any prior vaccination.~* Any fever, illness (including malaria).~* Receipt of another study vaccine within 30 days of study start.~* Chronic administration of an immunosuppressant or administration of immunoglobulins~* History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died suddenly without apparent cause.~* History of meningitis, seizures or any neurological disorder.~* Exposure to human immunodeficiency virus (HIV) by history.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 56 Days
- Healthy Volunteers: t

Study Arms:
- Pneumosil (Type: EXPERIMENTAL): Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
- Synflorix (Type: ACTIVE_COMPARATOR): Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
- Prevenar 13 (Type: ACTIVE_COMPARATOR): Infants received two primary vaccinations with Prevenar 13, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Established Status Epilepticus Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: Patient witnessed to seize for greater than 5 minute duration prior to treatment with study drug; Patient received adequate dose of benzodiazepines. The last dose of a benzo was administered in the 5-30 minutes prior to study drug administration. The doses may be divided.; continued or recurring seizure in the Emergency Department; Age 2 years or older~Exclusion Criteria:Known pregnancy; Prisoner; Opt-out identification; Treatment with a second line anticonvulsant (FOS, PHT, VPA, LEV, phenobarbital or other agents defined in the MoP) for this episode of SE; Treatment with sedatives with anticonvulsant properties other than benzodiazepines (propofol, etomidate, ketamine or other agents defined in the MoP); Endotracheal intubation; Acute traumatic brain injury; Known metabolic disorder; Known liver disease; Known severe renal impairment; Known allergy or other known contraindication to FOS, PHT, LEV, or VPA; Hypoglycemia \< 50 mg/dL; Hyperglycemia \> 400 mg/dL; Cardiac arrest and post-anoxic seizures

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosphenytoin (FOS) (Type: ACTIVE_COMPARATOR): Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
- Valproic acid (Type: ACTIVE_COMPARATOR): Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
- Levetiracetam (Type: ACTIVE_COMPARATOR): Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Insulin naïve~* Ongoing treatment with metformin or metformin in combination with either sulphonylurea (SU), glinides, dipeptidyl peptidase-IV (DPP-IV) inhibitors or exenatide (only twice daily (BID))~* Glycosylated haemoglobin (HbA1c) (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either SU, glinides, DPP-IV inhibitors or exenatide (only BID)~Exclusion Criteria:~* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks~* Calcitonin equal to or above 50 pg/mL~* Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks~* Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg + Lira (Type: EXPERIMENTAL): None
- Placebo + Lira (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Complications of Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18+~* Patients who were diagnosed with SCD confirmed by high-pressure liquid chromatography or hemoglobin electrophoresis will be eligible for the study~* Only patients in stable condition will be included~* Patients receiving transfusions will not be excluded~Exclusion Criteria:~* Patients with vaso-occlusive crises or an episode of acute chest syndrome within the previous four weeks (after 4 weeks have passed, the patients may be re-evaluated for eligibility)~* Patients with high degree heart block; active, hemodynamically significant, ventricular arrhythmias; unstable coronary syndromes; history of myocardial infarction within 1 month of the study.~* Contraindications to gadolinium-enhanced magnetic resonance examination such as severe claustrophobia, Pacemaker, defibrillators, cerebral aneurysm clips, or neurostimulator.~* Pregnancy~* Patients with sinus node dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Subjects with Sickle Cell Disease (SCD) (Type: None): 38 clinically stable black patients with Sickle Cell Disease (SCD) (including individuals with hemoglobin SS, SC, and β-thalassemia demonstrated by high-performance liquid chromatographic separation or gel electrophoresis).
- Healthy Volunteers (Type: None): 13 healthy control subjects were frequency matched to patients with SCD on age, sex, and race.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years old.~* Diagnosis of Chagas disease through two different serological tests.~* Positive T. cruzi PCR in peripheral blood.~* Signed informed consent.~Exclusion Criteria:~* Previous treatment with Benznidazole or Nifurtimox.~* Alcohol consumption.~* Acute or chronic health problems that could interfere in the assessment of the efficacy or safety of the drug (acute infections, HIV infection, liver or renal impairment, etc).~* Nitroimidazole hipersensitivity.~* Concomitant or previous treatment with allopurinol or antifungal drugs.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B300/60 (Type: ACTIVE_COMPARATOR): Benznidazole 300mg/day p.o. divided in two doses for 60 days
- B150/60 (Type: EXPERIMENTAL): Benznidazole 150mg/day p.o. divided in two doses for 60 days
- B400/15 (Type: EXPERIMENTAL): Benznidazole 400mg/day p.o. divided in two doses for 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with Myasthenia Gravis at least 6 months (180 days) prior to the date of the Screening Visit as confirmed by specific criteria.~2. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.~3. MG-ADL profile must be ≥ 6 at screening and randomization (Day 1).~4. Vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis).~Exclusion Criteria:~Medical Conditions~1. Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.~2. History of thymectomy within the 12 months prior to screening.~3. History of N meningitidis infection.~4. Use of the following within the time period specified below:~   * IV immunoglobulin within 4 weeks of randomization~  * Use of plasma exchange within 4 weeks of randomization~  * Use of rituximab within 6 months of screening~5. Participants who have received previous treatment with complement inhibitors (for example, eculizumab).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ravulizumab (Type: EXPERIMENTAL): Participants will receive ravulizumab for the duration of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive diagnosis of cirrhosis by US (coarse echogenic pattern, bulky caudate lobe, attenuated hepatic veins)~* Clinical manifestations of portal hypertension (as esophageal varices ,splenomegaly, ascites and encephalopathy grade I-II)~Exclusion Criteria:~* Pregnancy~* Hepatic encephalopathy grade III-IV~* Hepatocellular carcinoma~* Treatment with statins in the previous 3 months~* Hypersensitivity to statins~* Previous surgical shunt or TIPS~* Treatment with calcium channel blockers

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: ACTIVE_COMPARATOR): Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
- no treatment (Type: NO_INTERVENTION): no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: House Dust Mite Injection Immunotherapy in Elderly Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subjects had moderate or severe intermittent allergic rhinitis and fulfilled the Allergic Rhinitis and its Impact on Asthma (ARIA) criterion~* the patients included in the study all had a positive skin prick test (SPT), were positive for specific immunoglobulin E (sIgE), and had positive nasal provocation tests (NPTs) with D.pteronyssinus and D. farinae allergens.~Exclusion Criteria:~* Patients with a clinical allergy and/or a positive skin prick test and specific IgE to other inhalant allergens were excluded from the study. Additionally, patients with any of the following characteristics were also excluded: diagnosis of bronchial asthma, non-allergic rhinitis and severe non-stable diseases. Patients with other nasal problems, such as chronic nasal obstruction, reduced olfaction, bacterial colonization, and chronic sinusitis, were diagnosed based on a CT scan and nasal endoscopy were excluded. Subjects with other chronic or acute clinical disorders or with a history of respiratory tract infections within four weeks of the study initiation were also excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active AIT group (Type: ACTIVE_COMPARATOR): Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4
- non-active, placebo treatment (Type: PLACEBO_COMPARATOR): symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of 18 to 85 years of age (inclusive);~* Have a diagnosis of FAP~* Neuropathy Impairment Score requirement of 5-130~* Meet Karnofsky performance status requirements~* Have adequate complete blood counts and liver function tests~* Have adequate cardiac function~* Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)~Exclusion Criteria:~* Had a prior liver transplant or is planned to undergo liver transplant during the study period;~* Has untreated hypo- or hyperthyroidism;~* Has known human immunodeficiency virus (HIV) infection;~* Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;~* Recently received an investigational agent or device~* Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- patisiran (ALN-TTR02) (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete